secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-08-12T11:35:26+00:00
Accession:  0001193125-26-345753
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports Q2 2026 results; FDA clears IND for XTX501 bispecific PD-1/masked IL-2
--------------------------------------------------------------------------------

- FDA cleared IND for XTX501 (bispecific PD-1/masked IL-2); Phase 1/2 dosing expected 2H 2026 in NSCLC and solid tumors; initial data 2H 2027.
- Cash and equivalents $136.0M at 6/30/26 vs $137.5M at 12/31/25; runway into Q1 2028 (excl. warrant proceeds and milestones).
- Q2 2026 collaboration revenue $18.7M vs $8.1M YoY; net loss $6.4M vs $15.8M YoY.
- IND-enabling studies for masked TCEs targeting CLDN18.2 and PSMA+STEAP1; INDs planned 2H 2027.
- Appointed Ben Harshbarger as Chief Legal Officer in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/0001193125-26-345753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-345753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer